


## Bromelain

## Chemical Properties

|                   |                                                          |
|-------------------|----------------------------------------------------------|
| CAS No. :         | 9001-00-7                                                |
| Formula:          | C39H66N2O29                                              |
| Molecular Weight: | 1026.942                                                 |
| Appearance:       | no data available                                        |
| Storage:          | Powder: -20°C for 3 years   In solvent: -80°C for 1 year |



## Biological Description

|               |                                                                                                                                                                                                                                                                                                                                 |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description   | Bromelain is an anti-inflammatory drug derived from pineapple stem. It acts through down-regulation of plasma kininogen, degradation of advanced glycation end-product receptors, inhibition of Prostaglandin E2 expression, and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway. |
| Targets(IC50) | Apoptosis,Others                                                                                                                                                                                                                                                                                                                |
| In vivo       | Bromelain (40 mg/kg; i.p.; daily; for 7 days; male SD rats) pretreatment reduces the motor dysfunction in the parkinsonian rat model of Parkinson's disease. 6-OHDA injection resulted in a marked motor impairment which is prevented by pretreatment with Bromelain prior to the lesion [1].                                  |

## Solubility Information

|            |                                                                                                                          |
|------------|--------------------------------------------------------------------------------------------------------------------------|
| Solubility | DMSO: 3.33 mg/mL (3.25 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|--------------------------------------------------------------------------------------------------------------------------|

## Preparing Stock Solutions

|       | 1mg       | 5mg       | 10mg      |
|-------|-----------|-----------|-----------|
| 1 mM  | 0.9738 mL | 4.8688 mL | 9.7377 mL |
| 5 mM  | 0.1948 mL | 0.9738 mL | 1.9475 mL |
| 10 mM | 0.0974 mL | 0.4869 mL | 0.9738 mL |
| 50 mM | 0.0195 mL | 0.0974 mL | 0.1948 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

## Reference

Adu TS, et al. Effects of bromelain on motor responses following intra-medial forebrain bundle 6-OHDA injection in rat model of parkinsonism. Metab Brain Dis. 2019 Jul 22.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286    E\_mail:info@targetmol.com    Address:36 Washington Street,Wellesley Hills,MA 02481